Danaher Corporation acquired Cepheid for approximately $4.0 billion ($53.00 per share cash; including assumed debt and net of acquired cash), a transaction completed in November 2016, structured as all cash (tender offer and merger).
Cepheid operates in Diagnostics (molecular), is based in Sunnyvale, California, USA, had revenue of about $539 million (revenues). Danaher acquired Cepheid in 2016 for ~$4.0 billion; Cepheid is a leading global molecular diagnostics company that develops, manufactures and markets accurate, easy-to-use molecular systems and tests, now part of Danaher's Diagnostics segment.
Established Danaher's molecular diagnostics business, adding DNA-based testing systems for organisms and genetic diseases.
An indirect, wholly-owned subsidiary of the Company acquired all of the outstanding shares of common stock of Cepheid, a California corporation, for $53.00 per share in cash, for a total purchase price of approximately $4.0 billion, including assumed debt and net of acquired cash (the “Cepheid Acquisition”).Danaher Corporation FY16 10-K, acquisition note
Advisory firms were not disclosed for this transaction.